31Mar/08
Cholesterol DrugsTake a Fall
The marketing of Vytorin and Zetia raced ahead of the science. Now Schering and Merck shareholders are $22 billion poorer
The marketing of Vytorin and Zetia raced ahead of the science. Now Schering and Merck shareholders are $22 billion poorer